share_log

Climb Bio Q4 2024 GAAP EPS $(0.13) Beats $(0.15) Estimate

Benzinga ·  Mar 25 20:08

Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is unchanged from the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 375

Recommended

Write a comment